Syros Pharmaceuticals Inc (NASDAQ:SYRS) – Research analysts at Wedbush raised their Q1 2018 EPS estimates for Syros Pharmaceuticals in a research note issued on Tuesday. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.16) for the quarter, up from their previous estimate of ($0.46). Wedbush also issued estimates for Syros Pharmaceuticals’ Q2 2018 earnings at ($0.62) EPS, Q3 2018 earnings at ($0.58) EPS, Q4 2018 earnings at ($0.64) EPS, FY2018 earnings at ($2.00) EPS, FY2019 earnings at ($2.21) EPS, FY2020 earnings at ($1.95) EPS and FY2021 earnings at ($1.79) EPS.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.53).
Shares of Syros Pharmaceuticals (NASDAQ:SYRS) traded down $0.08 during mid-day trading on Thursday, hitting $10.65. The company’s stock had a trading volume of 270,500 shares, compared to its average volume of 252,275. Syros Pharmaceuticals has a twelve month low of $6.30 and a twelve month high of $24.38. The stock has a market cap of $280.06 and a PE ratio of -6.12.
In related news, insider Jeremy P. Springhorn acquired 15,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was purchased at an average cost of $9.08 per share, for a total transaction of $136,200.00. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Srinivas Akkaraju acquired 109,774 shares of the firm’s stock in a transaction that occurred on Thursday, December 14th. The shares were bought at an average price of $9.03 per share, with a total value of $991,259.22. The disclosure for this purchase can be found here. Corporate insiders own 33.60% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of SYRS. Schwab Charles Investment Management Inc. purchased a new stake in shares of Syros Pharmaceuticals during the 2nd quarter worth $343,000. Rhumbline Advisers acquired a new position in Syros Pharmaceuticals during the 2nd quarter valued at about $198,000. Bank of New York Mellon Corp increased its position in Syros Pharmaceuticals by 157.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 30,024 shares of the company’s stock valued at $483,000 after buying an additional 18,382 shares in the last quarter. Teachers Advisors LLC increased its position in Syros Pharmaceuticals by 360.5% during the 2nd quarter. Teachers Advisors LLC now owns 22,718 shares of the company’s stock valued at $366,000 after buying an additional 17,785 shares in the last quarter. Finally, TIAA CREF Investment Management LLC increased its position in Syros Pharmaceuticals by 646.3% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 34,390 shares of the company’s stock valued at $553,000 after buying an additional 29,782 shares in the last quarter. Hedge funds and other institutional investors own 57.96% of the company’s stock.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.